Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
Zheng Quan Toh1,2, Jennie Kosasih,1 Fiona M Russell1,3, Suzanne M Garland4,5, Edward K Mulholland1,6, Paul V Licciardi1,21Infection and Immunity, Murdoch Children’s Research Institute, Parkville, Victoria, Australia; 2Department of Paediatrics, The University of Melbourne, Parkville, Victo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-07-01
|
| Series: | Infection and Drug Resistance |
| Subjects: | |
| Online Access: | https://www.dovepress.com/recombinant-human-papillomavirus-nonavalent-vaccine-in-the-prevention--peer-reviewed-article-IDR |
| _version_ | 1831637494811066368 |
|---|---|
| author | Toh ZQ Kosasih J Russell FM Garland SM Mulholland EK Licciardi PV |
| author_facet | Toh ZQ Kosasih J Russell FM Garland SM Mulholland EK Licciardi PV |
| author_sort | Toh ZQ |
| collection | DOAJ |
| description | Zheng Quan Toh1,2, Jennie Kosasih,1 Fiona M Russell1,3, Suzanne M Garland4,5, Edward K Mulholland1,6, Paul V Licciardi1,21Infection and Immunity, Murdoch Children’s Research Institute, Parkville, Victoria, Australia; 2Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; 3Centre for International Child Health, Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; 4Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia; 5Regional WHO HPV Reference Laboratory, Centre for Women’s Infectious Diseases Research, The Royal Women’s Hospital, Parkville, Victoria, Australia; 6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, University of London, London WC1E7HT, UKAbstract: Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of cervical cancer cases, as well as a significant proportion of other HPV-related anogenital cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine efficacy against HPV infection and related anogenital precancers, safety, and immunogenicity, as well as discussing the potential impact of this vaccine on the cervical cancer burden globally.Keywords: nonavalent human papillomavirus vaccine, review, efficacy, immunogenicity, safety |
| first_indexed | 2024-12-19T06:52:26Z |
| format | Article |
| id | doaj.art-80811cdea05d4a52bf94ed371b4a67b5 |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-12-19T06:52:26Z |
| publishDate | 2019-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-80811cdea05d4a52bf94ed371b4a67b52022-12-21T20:31:40ZengDove Medical PressInfection and Drug Resistance1178-69732019-07-01Volume 121951196746850Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirusToh ZQKosasih JRussell FMGarland SMMulholland EKLicciardi PVZheng Quan Toh1,2, Jennie Kosasih,1 Fiona M Russell1,3, Suzanne M Garland4,5, Edward K Mulholland1,6, Paul V Licciardi1,21Infection and Immunity, Murdoch Children’s Research Institute, Parkville, Victoria, Australia; 2Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; 3Centre for International Child Health, Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; 4Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia; 5Regional WHO HPV Reference Laboratory, Centre for Women’s Infectious Diseases Research, The Royal Women’s Hospital, Parkville, Victoria, Australia; 6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, University of London, London WC1E7HT, UKAbstract: Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of cervical cancer cases, as well as a significant proportion of other HPV-related anogenital cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine efficacy against HPV infection and related anogenital precancers, safety, and immunogenicity, as well as discussing the potential impact of this vaccine on the cervical cancer burden globally.Keywords: nonavalent human papillomavirus vaccine, review, efficacy, immunogenicity, safetyhttps://www.dovepress.com/recombinant-human-papillomavirus-nonavalent-vaccine-in-the-prevention--peer-reviewed-article-IDRnine-valentHPV vaccinereviewefficacy and immunogenicity |
| spellingShingle | Toh ZQ Kosasih J Russell FM Garland SM Mulholland EK Licciardi PV Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus Infection and Drug Resistance nine-valent HPV vaccine review efficacy and immunogenicity |
| title | Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus |
| title_full | Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus |
| title_fullStr | Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus |
| title_full_unstemmed | Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus |
| title_short | Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus |
| title_sort | recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus |
| topic | nine-valent HPV vaccine review efficacy and immunogenicity |
| url | https://www.dovepress.com/recombinant-human-papillomavirus-nonavalent-vaccine-in-the-prevention--peer-reviewed-article-IDR |
| work_keys_str_mv | AT tohzq recombinanthumanpapillomavirusnonavalentvaccineinthepreventionofcancerscausedbyhumanpapillomavirus AT kosasihj recombinanthumanpapillomavirusnonavalentvaccineinthepreventionofcancerscausedbyhumanpapillomavirus AT russellfm recombinanthumanpapillomavirusnonavalentvaccineinthepreventionofcancerscausedbyhumanpapillomavirus AT garlandsm recombinanthumanpapillomavirusnonavalentvaccineinthepreventionofcancerscausedbyhumanpapillomavirus AT mulhollandek recombinanthumanpapillomavirusnonavalentvaccineinthepreventionofcancerscausedbyhumanpapillomavirus AT licciardipv recombinanthumanpapillomavirusnonavalentvaccineinthepreventionofcancerscausedbyhumanpapillomavirus |